腹膜假性黏液瘤的治疗及预后分析  

Treatment and prognosis of pseudomyxoma peritonei

作　　者：王尧[1] 方国恩[1] 章琎[2] 薛绪潮 毕建威[1] 

机构地区：[1]第二军医大学附属长海医院普外一科,上海200433 [2]第二军医大学附属东方肝胆外科医院,上海200433

出　　处：《中国实用外科杂志》2010年第1期57-58,62,共3页Chinese Journal of Practical Surgery

摘　　要：目的总结探讨腹膜假性黏液瘤治疗的经验及预后。方法回顾性分析1990年1月至2007年12月第二军医大学长海医院收治的42例腹膜假性黏液瘤病人的治疗及随访情况。结果42例病人均经手术治疗,其中23例仅行细胞减灭术(CRS组),19例行细胞减灭术及术中腹腔温热化疗(CRS+IPHC组)。全部病人无手术死亡,随访1～16(平均6.8)年。其中CRS+IPHC组与CRS组的1年存活率比较差异无统计学意义(P>0.05),CRS+IPHC组3、5年存活率显著高于CRS组(P<0.05),复发率显著低于CRS组(P<0.05)。结论细胞减灭术辅以术中腹腔温热化疗可提高腹膜假性黏液瘤病人的存活率。Objective To summarize the experience of treating pseudomyxoma peritonei （PMP） and analyzed the prognosis. Methods A total of42 patients with pseudomyxoma peritonei（PMP）treated in our hospital from 1990-2008 were analyzed retrospectively. OF the 42 patients , 21 underwent cytoreductive surgery（CRS group）,19 underwent CRS and intraoperative peritoneal hyperthermia-chemotherapy（CRS ＋ IPHC group）.The median follow-up period was 6.8 years（range, 1 - 16 years）. Results There was no significant difference in 1-year survival rate between the CRS group and CRS ＋ IPHC group（P〉0.05）.The 3,5-year survival rates were significant higher in CRS ＋ IPHC group than in CRS group, while the recurrence rate was in contrast （P〈0.05）. Conclusions The using of CRS and IPHC might improve the survival rate of patients with PMP.

关 键 词：腹膜假性黏液瘤 细胞减灭术 腹腔温热化疗 

分 类 号：R6[医药卫生—外科学]